Outlook Therapeutics (OTLK) Operating Expenses: 2015-2020
Historic Operating Expenses for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to $10.0 million.
- Outlook Therapeutics' Operating Expenses fell 46.00% to $10.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $36.8 million, marking a year-over-year decrease of 17.11%. This contributed to the annual value of $71.7 million for FY2024, which is 34.97% up from last year.
- Latest data reveals that Outlook Therapeutics reported Operating Expenses of $10.0 million as of Q3 2020, which was down 15.70% from $11.9 million recorded in Q2 2020.
- In the past 5 years, Outlook Therapeutics' Operating Expenses ranged from a high of $22.5 million in Q2 2016 and a low of $3.9 million during Q1 2016.
- Moreover, its 3-year median value for Operating Expenses was $8.3 million (2019), whereas its average is $10.0 million.
- Its Operating Expenses has fluctuated over the past 5 years, first plummeted by 78.17% in 2017, then spiked by 186.59% in 2018.
- Over the past 5 years, Outlook Therapeutics' Operating Expenses (Quarterly) stood at $18.1 million in 2016, then plummeted by 78.17% to $4.0 million in 2017, then skyrocketed by 186.59% to $11.3 million in 2018, then fell by 27.73% to $8.2 million in 2019, then tumbled by 46.00% to $10.0 million in 2020.
- Its Operating Expenses was $10.0 million in Q3 2020, compared to $11.9 million in Q2 2020 and $6.8 million in Q1 2020.